© 2005 Oxford University Press
REVIEW |
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
Affiliations of authors: Division of Epigenetics, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld, Heidelberg, Germany (FL); Centre for Oncology and Applied Pharmacology, CRUK Beatson Labs, Glasgow University, Glasgow, UK (RB)
Correspondence to: Frank Lyko, PhD, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany (e-mail: f.lyko{at}dkfz.de).
Epimutations, such as the hypermethylation and epigenetic silencing of tumor suppressor genes, play a role in the etiology of human cancers. In contrast to DNA mutations, which are passively inherited through DNA replication, epimutations must be actively maintained because they are reversible. In fact, the reversibility of epimutations by small-molecule inhibitors provides the foundation for the use of such inhibitors in novel cancer therapy strategies. Among the compounds that inhibit epigenetic processes, the most extensively studied are DNA methyltransferase inhibitors. In this review, we examine the literature on DNA methyltransferase inhibitors and discuss the efficacy of such compounds as antitumor agents, as evaluated in phase I–III clinical trials. We also discuss future areas of research, including the development of nonnucleoside inhibitors, the application of novel bioanalytical tools for DNA methylation analysis (which will be important for the clinical application of these compounds by allowing rational approaches to trial design), the need to optimize treatment schedules for maximal biologic effectiveness, and the need to define molecular endpoints so that changes induced by demethylating drugs in patients can be monitored during treatment. Assays for genome-wide and tumor-specific DNA methylation also need to be further developed to establish the pharmacodynamic parameters of DNA methyltransferase inhibitors in patients and to provide rational approaches to maximizing the therapeutic efficacy of these compounds.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. P. Garrison, J. R. Jeffers, C. Yang, J. A. Nilsson, M. A. Hall, J. E. Rehg, W. Yue, J. Yu, L. Zhang, M. Onciu, et al. Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis Mol. Cell. Biol., September 1, 2008; 28(17): 5391 - 5402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hadnagy, R. Beaulieu, and D. Balicki Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics Mol. Cancer Ther., April 1, 2008; 7(4): 740 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Appleton, H. J. Mackay, I. Judson, J. A. Plumb, C. McCormick, G. Strathdee, C. Lee, S. Barrett, S. Reade, D. Jadayel, et al. Phase I and Pharmacodynamic Trial of the DNA Methyltransferase Inhibitor Decitabine and Carboplatin in Solid Tumors J. Clin. Oncol., October 10, 2007; 25(29): 4603 - 4609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Brown and R Glasspool Epigenetic modulation of resistance to chemotherapy? Ann. Onc., September 1, 2007; 18(9): 1429 - 1430. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Filomeni, G. Cerchiaro, A. M. Da Costa Ferreira, A. De Martino, J. Z. Pedersen, G. Rotilio, and M. R. Ciriolo Pro-apoptotic Activity of Novel Isatin-Schiff Base Copper(II) Complexes Depends on Oxidative Stress Induction and Organelle-selective Damage J. Biol. Chem., April 20, 2007; 282(16): 12010 - 12021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ghochikyan, M. Mkrtichyan, D. Loukinov, G. Mamikonyan, S. D. Pack, N. Movsesyan, T. E. Ichim, D. H. Cribbs, V. V. Lobanenkov, and M. G. Agadjanyan Elicitation of T Cell Responses to Histologically Unrelated Tumors by Immunization with the Novel Cancer-Testis Antigen, Brother of the Regulator of Imprinted Sites J. Immunol., January 1, 2007; 178(1): 566 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J L Wong, N J Hawkins, and R L Ward Colorectal cancer: a model for epigenetic tumorigenesis Gut, January 1, 2007; 56(1): 140 - 148. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Iliopoulos, M. Fabbri, T. Druck, H. R. Qin, S.-Y. Han, and K. Huebner Inhibition of Breast Cancer Cell Growth In vitro and In vivo: Effect of Restoration of Wwox Expression Clin. Cancer Res., January 1, 2007; 13(1): 268 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Beumer, J. L. Eiseman, R. A. Parise, E. Joseph, J. L. Holleran, J. M. Covey, and M. J. Egorin Pharmacokinetics, Metabolism, and Oral Bioavailability of the DNA Methyltransferase Inhibitor 5-Fluoro-2'-Deoxycytidine in Mice Clin. Cancer Res., December 15, 2006; 12(24): 7483 - 7491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.M. Ordway, J.A. Bedell, R.W. Citek, A. Nunberg, A. Garrido, R. Kendall, J.R. Stevens, D. Cao, R.W. Doerge, Y. Korshunova, et al. Comprehensive DNA methylation profiling in a human cancer genome identifies novel epigenetic targets Carcinogenesis, December 1, 2006; 27(12): 2409 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, V. Pishchik, et al. Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura. Clin. Cancer Res., October 1, 2006; 12(19): 5777 - 5785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stresemann, B. Brueckner, T. Musch, H. Stopper, and F. Lyko Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res., March 1, 2006; 66(5): 2794 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Xi, K. F. Dyer, M. Kimak, Q. Zhang, W. E. Gooding, J. R. Chaillet, R. L. Chai, R. E. Ferrell, B. Zamboni, J. Hunt, et al. Decreased STAT1 Expression by Promoter Methylation in Squamous Cell Carcinogenesis J Natl Cancer Inst, February 1, 2006; 98(3): 181 - 189. [Abstract] [Full Text] [PDF]
|
|